|Free Dividend Report|
|Stock Splits Calendar|
|ADRO Stock Split History|
|Preferred Stock Newsletter|
|ADRO Options Chain|
|Stock Message Boards|
ADRO (ADRO) has 1 split in our ADRO split history database. The split for ADRO took place on October 02, 2020. This was a 1 for 5 reverse split, meaning for each 5 shares of ADRO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.
When a company such as ADRO conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ADRO split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ADRO shares, starting with a $10,000 purchase of ADRO, presented on a split-history-adjusted basis factoring in the complete ADRO split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-38.53%|
|Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies for the treatment of patients with diseases. Co.'s product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. Co.'s key STING pathway activator product candidate, ADU-S100 (MIW815), is designed to selectively modulate innate and adaptive immune responses to enhance immune control in oncology. Co.'s anti-APRIL antibody product candidate, BION-1301, is designed to suppress the autoimmune response in patients with IgA nephropathy. According to our ADRO split history records, ADRO has had 1 split.|
|ADRO Split History Table|
|10/02/2020||1 for 5|
|Healthcare Stock Splits|
|ADRO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: ADRO shares outstanding history